Fitness coach shares 13 fat loss cheat codes to lose weight faster: 'Water matters more than you think'
Mahtab Ekay is an online fitness coach, who 'helps busy women lose 20 pounds (9 kg) or more without giving up their favourite food'. She has herself shed over 55 pounds (24.9 kg). In an Instagram post on May 5, Mahtab shared tips for faster weight loss. Also read | Want a flat tummy? Fitness trainer shares 5 tips to help lose belly fat: 'Avoid drinking your calories' Water plays a significant role in weight loss. Here's what a fitness coach has said. (Representative picture: Freepik)
According to her, you should drink plenty of water throughout the day to boost metabolism and include protein in your every meal to build muscle and reduce hunger. In her post titled 'Fat loss cheat codes I know at 28 that I wish I knew at 18', Mahtab wrote: 'Make sleep part of your fat loss plan'
1. If you're not seeing results, it's probably a consistency issue, not your metabolism.
2. You don't need to work out every day. 3–4 solid sessions with a plan > random daily workouts.
3. Include 20–30g of protein in every meal. This helps with fat loss, muscle gain, and cravings.
4. Sleep is not a luxury. It's part of your fat loss plan.
5. You can't 'burn off' a weekend binge. One meal doesn't ruin progress, what you do next matters more.
6. Carbs are not the enemy. Balanced meals and calorie intake matter more than cutting rice or bread.
7. Water matters more than you think. Aim for half your body weight (pounds) in ounces daily. 'Walking is underrated'
8. You don't need to track carbs and fats perfectly. Calories + protein = 90% of the results.
9. Intermittent fasting isn't magic. If it works for you, great. If not, skip it.
10. Walking is underrated. A 20–30 min daily walk helps with digestion, cravings, and fat loss.
11. Fiber is your friend. Aim for 25–35g daily from real food.
12. You don't need a perfect meal plan. Just 2–3 go-to meals you enjoy and can rotate.
13. The best plan is the one you can stick to. Not the most intense one.
Click here for more 'fat loss cheat codes that actually work', which were shared by US-based fitness coach Dan Go in an Instagram post on March 1.
Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
11 minutes ago
- Economic Times
KKR-backed IVI to buy ART Fertility Clinics for $450 million
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel KKR-backed IVI RMA Global, a US-based leader in infertility treatment, is set to acquire ART Fertility Clinics for $400-450 million, according to people familiar with the matter. The acquisition marks a significant step in IVI RMA's global expansion, adding India to its presence in over 15 countries and more than 190 clinical offices across the US, Europe and Latin parties are in the final stages of documentation for a shareholders' agreement and are hoping to wrap up the transaction by June with private hospitals, the IVF industry in India too is witnessing consolidation as several private equity funds have been aggressive with acquisitions. In 2023, Swedish fund EQT Partners acquired a significant majority stake in Indira IVF, the largest provider of fertility services in India and top five globally in terms of annual IVF cycles, at a $1.1 billion ('9,000 crore) Fertility Clinics began in 2015 as IVI Middle East, an international arm of IVI RMA Global. In 2020, IVI RMA divested the business to Gulf Capital, which rebranded it as ART Fertility Clinics. Since then, the brand has rapidly grown, expanding across West Asia and clinics in Abu Dhabi, Dubai and Al Ain in the UAE as well as 11 centres across India, ART Fertility has established itself as a high-performance network in reproductive medicine. The Indian expansion began in 2021, backed by a $30 million investment from Gulf Fertility operates in big Indian cities including Mumbai, Noida, Ahmedabad, Chennai, Hyderabad, Gurgaon and by Suresh Soni, former co-founder and CEO of Nova IVF Fertility, ART Fertility reports a pregnancy success rate of 70% and has recorded over 5,000 successful pregnancies in under nine to sources, ART Fertility posted revenue of $100-120 million in FY25, with an estimated Ebitda of $35 million."For an Indian healthcare player, a $25-35 million ebitda which is borderline ebitda positive coming from the Middle East would add no value," said a fund manager at a Mumbai-based private equity firm that operates a pan-India IVF chain. "However, IVI being a US player where multiples are low, adding a Middle East business works well."IVI RMA trumped a rival bid by Temasek-backed Cloudnine Hospitals.A KKR spokesperson declined to comment. IVI RMA and ART Fertility did not respond to is the advisor in the is rapidly emerging as one of the world's fastest-growing markets for Assisted Reproductive Technology (ART). However, the sector has scope for expansion at 210 IVF cycles per million people, compared with 1,200 in the US and over 2,000 in affects approximately 15% of Indian couples, a figure expected to rise due to lifestyle factors such as poor diet, stress, late marriages, and to EY, India's IVF market is expected to grow from $793 million in 2020 to $1.45 billion by 2027, at a projected CAGR of 15-20%.India sees around 300,000 IVF cycles annually, with projections suggesting this could grow to 500,000-600,000 cycles by 2030. About 30% of the market is controlled by 10-15 organised players, while the remaining is fragmented among smaller, unorganised clinics. Key players in India's fertility sector include Indira IVF, Nova IVF, Oasis IVF, Bloom Fertility Centre, Bengaluru-based Milann, Morpheus IVF, Ridge IVF, Akanksha IVF and Bourn Hall IVF, the second largest player in India, is owned by Asia Healthcare Holdings (AHH), the single specialty hospitals platform backed by GIC and homegrown PE fund Kedaara Capital owns a minority stake in Oasis Fertility, while Brussels-based fund Verlinvest owns a controlling stake in Ferty9 F, a premier chain of fertility clinics in the AP/Telangana region.
Time of India
an hour ago
- Time of India
KKR-backed IVI to buy ART Fertility Clinics for $450 million
KKR-backed IVI RMA Global, a US-based leader in infertility treatment, is set to acquire ART Fertility Clinics for $400-450 million, according to people familiar with the matter. The acquisition marks a significant step in IVI RMA's global expansion, adding India to its presence in over 15 countries and more than 190 clinical offices across the US, Europe and Latin America. Both parties are in the final stages of documentation for a shareholders' agreement and are hoping to wrap up the transaction by June end. As with private hospitals, the IVF industry in India too is witnessing consolidation as several private equity funds have been aggressive with acquisitions. In 2023, Swedish fund EQT Partners acquired a significant majority stake in Indira IVF, the largest provider of fertility services in India and top five globally in terms of annual IVF cycles, at a $1.1 billion ('9,000 crore) valuation. ART Fertility Clinics began in 2015 as IVI Middle East, an international arm of IVI RMA Global. In 2020, IVI RMA divested the business to Gulf Capital, which rebranded it as ART Fertility Clinics. Since then, the brand has rapidly grown, expanding across West Asia and India. Live Events With clinics in Abu Dhabi, Dubai and Al Ain in the UAE as well as 11 centres across India, ART Fertility has established itself as a high-performance network in reproductive medicine. The Indian expansion began in 2021, backed by a $30 million investment from Gulf Capital. ART Fertility operates in big Indian cities including Mumbai, Noida, Ahmedabad, Chennai, Hyderabad, Gurgaon and Faridabad. Led by Suresh Soni, former co-founder and CEO of Nova IVF Fertility, ART Fertility reports a pregnancy success rate of 70% and has recorded over 5,000 successful pregnancies in under nine years. According to sources, ART Fertility posted revenue of $100-120 million in FY25, with an estimated Ebitda of $35 million. "For an Indian healthcare player, a $25-35 million ebitda which is borderline ebitda positive coming from the Middle East would add no value," said a fund manager at a Mumbai-based private equity firm that operates a pan-India IVF chain. "However, IVI being a US player where multiples are low, adding a Middle East business works well." IVI RMA trumped a rival bid by Temasek-backed Cloudnine Hospitals. A KKR spokesperson declined to comment. IVI RMA and ART Fertility did not respond to queries. Moelis is the advisor in the transaction. India is rapidly emerging as one of the world's fastest-growing markets for Assisted Reproductive Technology (ART). However, the sector has scope for expansion at 210 IVF cycles per million people, compared with 1,200 in the US and over 2,000 in Europe. Infertility affects approximately 15% of Indian couples, a figure expected to rise due to lifestyle factors such as poor diet, stress, late marriages, and pollution. According to EY, India's IVF market is expected to grow from $793 million in 2020 to $1.45 billion by 2027, at a projected CAGR of 15-20%. India sees around 300,000 IVF cycles annually, with projections suggesting this could grow to 500,000-600,000 cycles by 2030. About 30% of the market is controlled by 10-15 organised players, while the remaining is fragmented among smaller, unorganised clinics. Key players in India's fertility sector include Indira IVF, Nova IVF, Oasis IVF, Bloom Fertility Centre, Bengaluru-based Milann, Morpheus IVF, Ridge IVF, Akanksha IVF and Bourn Hall Clinic. Nova IVF, the second largest player in India, is owned by Asia Healthcare Holdings (AHH), the single specialty hospitals platform backed by GIC and TPG. Similarly, homegrown PE fund Kedaara Capital owns a minority stake in Oasis Fertility, while Brussels-based fund Verlinvest owns a controlling stake in Ferty9 F, a premier chain of fertility clinics in the AP/Telangana region.
Time of India
2 hours ago
- Time of India
DCA seizes stocks of banned medicated soap
1 2 3 H yderabad: The Drugs Control Administration (DCA) officials in Karimnagar conducted a raid and seized stocks of a banned medicated soap that was being sold illegally on Sunday. Acting on a tip-off, they raided PLN Pharma Distributors in Karimnagar and found Dr Ethix's MediSkin Medicated Soap, which contains the prohibited combination of permethrin, cetrimide and menthol. The soap had been illegally manufactured by Maxwell Pharma in Solan, Himachal Pradesh, for the Chennai-based company Dr Ethix Products and Services. According to officials, this specific drug combination was banned by the central government in 2018 due to a lack of therapeutic justification and public health concerns. The prohibition covers the manufacture, distribution and sale of the soap for human use across the country. Further investigation is being carried out on the drug samples collected.
